9 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 6 Not applicable, 3 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 3, Recruiting 2, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Drug-resistant Tuberculosis: new trials by email Literature Review of Drug-resistant Tuberculosis trials Research Report on Drug-resistant Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis Therapeutic Drug Monitoring for Linezolid - Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis | Not applicable | Recruiting | Albert Einstein College of Medicine | 280 | 2026-04-07 | 2026-05-04 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort BLMZ - Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Beijing Chest Hospital | 120 | 2025-12-01 | 2025-12-08 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis Targeted next-generation sequencing - Drug-resistant Tuberculosis, HIV Coinfection | Not applicable | Recruiting | University of California, San Francisco | 2500 | 2024-08-01 | 2026-01-26 |
| Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis JDB0131, Delamanid, Ethylpyrazine rifampicide (II) - Drug-resistant Tuberculosis | Phase 2 | Unknown | Beijing Chest Hospital | 52 | 2023-10-31 | 2024-01-25 |
| A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults TBAJ-876, Midazolam, Digoxin - Pulmonary Disease, Tuberculosis, Pulmonary | Phase 1 | Completed | Global Alliance for TB Drug Development | 28 | 2022-06-30 | 2024-10-08 |
| Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial WGS DST strategy - Rifampicin Resistant Tuberculosis, Drug-resistant Tuberculosis | Not applicable | Unknown | Universiteit Antwerpen | 248 | 2021-09-21 | 2021-10-15 |
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 | Completed | Global Alliance for TB Drug Development | 26 | 2021-09-16 | 2025-01-17 |
| Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet - Pulmonary Disease, Tuberculosis, Pulmonary | Phase 1 | Completed | Global Alliance for TB Drug Development | 137 | 2020-06-08 | 2025-06-04 |
| Evaluation of Centralised TB Assay Solutions Tuberculosis, Drug-resistant Tuberculosis | Completed | Foundation for Innovative New Diagnostics, Switzerland | 1050 | 2019-05-20 | 2023-11-18 | |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Completed | Global Alliance for TB Drug Development | 455 | 2018-07-30 | 2026-08-27 |
| Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes Keheala Mobile Health Platform and Behavioral Interventions, Social and Behavior Change Communication (SBCC), SMS Reminder - Tuberculosis, Adherence, Patient | Not applicable | Completed | Massachusetts Institute of Technology | 16146 | 2018-04-13 | 2022-01-21 |
| An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment Electronic DOT, In-person DOT - Tuberculosis, Drug-resistant Tuberculosis | Not applicable | Completed | Centers for Disease Control and Prevention | 216 | 2017-07-19 | 2026-07-02 |
| Brief Bactericidal Activity of Anti-Tuberculosis Drugs High dose isoniazid - Tuberculosis, Drug-resistant Tuberculosis | Phase 1 | Completed | Centers for Disease Control and Prevention | 18 | 2015-11-01 | 2020-10-19 |
| Rewards for Tuberculosis Contact Screening Contacts, Index - Tuberculosis, Drug-resistant Tuberculosis | Not applicable | Completed | Boston University | 301 | 2014-10-01 | 2021-01-08 |
Tuberculosis, Multidrug-Resistant (15) · Tuberculosis (10) · Tuberculosis, Pulmonary (7) · Lung Diseases (2) · Medication Adherence (2) · Patient Compliance (2) · Directly Observed Therapy (1) · Extensively Drug-Resistant Tuberculosis (1) · HIV Infections (1)
Actinomycetales Infections (15) · Bacterial Infections (15) · Bacterial Infections and Mycoses (15) · Gram-Positive Bacterial Infections (15) · Infections (15) · Mycobacterium Infections (15) · Respiratory Tract Diseases (7) · Respiratory Tract Infections (7) · Lung Diseases (5) · Tuberculosis (5) · Behavior (2) · Health Behavior (2) · Patient Acceptance of Health Care (2) · Treatment Adherence and Compliance (2) · Blood-Borne Infections (1)
bedaquiline (3) · Isoniazid (2) · Linezolid (2) · Moxifloxacin (2) · OPC-67683 (2) · Pyrazinamide (2) · TBAJ-876 (2) · pretomanid (2) · Behavior Therapy (1) · Clofazimine (1) · Digoxin (1) · Ethambutol (1) · Fumigant 93 (1) · Levofloxacin (1) · Midazolam (1)
Global Alliance for TB Drug Development (4) · Beijing Chest Hospital (2) · Centers for Disease Control and Prevention (2) · Albert Einstein College of Medicine (1) · Boston University (1) · Foundation for Innovative New Diagnostics, Switzerland (1) · Huashan Hospital (1) · Massachusetts Institute of Technology (1) · Universiteit Antwerpen (1) · University of California, San Francisco (1)
South Africa (7) · China (3) · Georgia (3) · United States (3) · India (2) · Brazil (1) · Germany (1) · Kenya (1) · Malaysia (1) · Moldova (1) · Philippines (1) · Russia (1) · Tanzania (1) · Uganda (1)
Antonio Lombardi, MD (3) · Annelies Van Rie, PhD, MD (1) · Gary Maartens, MBChB (1) · Gavin Churchyard, PhD, MD (1) · J. P. Cegielski, MD, MPH (1) · James CM Brust, MD (1) · John Z Metcalfe, MD, PhD (1) · Joseph Burzynski, MD, MPH (1) · Morounfolu Olugbosi, MD MSc (1) · Rob M Warren, PhD (1) · Salome Charalambous, PhD (1) · Sarah E. Smith-Jeffcoat, MPH (1) · Sydney Rosen (1)
PMID 35050357, PMID 36209235, PMID 37035970, PMID 38768617, PMID 39194204, PMID 41461639, PMID 42026006
R01AI153213 (1), R01AI184416 (1), U01AI100015 (1)